[surassawadee/Adobe Stock]
In 2023, generative AI (GenAI) entered the mainstream, capturing the attention of both the public and a growing number of biotechs. One of the most prominent Big Tech firms driving the trend is NVIDIA, which has forged alliances with biotechs ranging from Genentech, Recursion Pharmaceuticals and Evozyne, among others.The momentum is continuing in early 2024, with NVIDIA announcing renewed pacts with Amgen and DeepCell. Amgen will use NVIDIA’s drug discovery generative AI platform BioNeMo Cloud service to accelerate molecule screening and optimization processes. Meanwhile, NVIDIA’s partnership with Deepcell hinges on advancing cell morphology studies with generative AI. “There is a very big moment happening in the world of pharmaceuticals and how drugs are being discovered,” said Kimberly Powell, vice president of Healthcare at NVIDIA, in a call with journali…